Vaccines

(A-339) 2024 interim results from the VAC4EU post-authorisation safety study (PASS) for the Pfizer-BioNTech COVID-19 vaccine (Comirnaty®) in Europe

(SLC-051) A Pregnancy Registry to Evaluate the Safety of CYD Tetravalent Dengue Vaccine among Inadvertently Exposed Pregnant Women and their Offspring

(C-253) Active and Passive Safety Surveillance in Children Receiving Fluenz® Tetra Vaccination in England During Influenza Seasons - from 2014/2015 to 2022/2023

(A-353) Application of the Actor-Partner Interdependence Model to Understand COVID-19 Vaccine Decision-Making among Adolescents and their Parents

(C-255) Assessing Knowledge, Attitude and Practice on Human Papilloma Virus Vaccination Among Medical Students at the University of Nairobi

(A-349) Assessing the Association Between COVID-19 Vaccination and Thrombotic Thrombocytopenia Syndrome (ATTEST Study): Analyses of English Data, 2020–2022

(A-357) Assessment of the Risk of 32 Adverse Effects of Special Interest following COVID-19 Vaccination in the Whole French Population

(A-345) Assessment of the Safety of Human Papillomavirus Vaccination in Japan: VENUS Study

(A-351) Autoimmune Disease Risks Across COVID-19 Vaccine Platforms: A Population-Based Cohort Study in Taiwan

(A-346) Background Rates of Adverse Events for Vaccine Safety Monitoring at Two Sentinel Hospitals in Addis Ababa, Ethiopia

(A-352) Barriers and Strategies to Improve Vaccine Adverse Events Reporting: Views from Health Workers and Managers in Northern Ghana

(A-350) Baseline Characteristics of Patients Included in a Post-Approval Safety Study of Pfizer-BioNTech Monovalent COVID-19 Vaccine in the United States: Results From an Interim Analysis

(A-340) Characterizing background risk of febrile seizure among pediatric patients during routine clinical care and vaccination

(SLC-055) Clinical course and outcomes of myocarditis/pericarditis cases following mRNA-1273 vaccination compared to cases not following COVID-19 vaccination: interim analysis of a VAC4EU cohort study

(C-254) Concomitant COVID-19 and Influenza Vaccination and the Risk of Psychiatric Adverse Events: a nationwide self-controlled case series study

(SLC-056) COVID-19 vaccine effectiveness against Post COVID-19 condition among 1,292,557 individuals with pre-existing immunity against SARS-CoV-2: a population-based cohort study.

(A-337) Dependence of the Data Source on the Positive Predictive Value in the Retrospective Case Validation of Thrombosis and Thrombocytopenia Syndrome cases using Real-World Data

(A-343) Developing the Framework of Epidemiological and Biostatistical Approaches for Post-Approval Vaccine Safety Assessment Using a Large Healthcare Database in Japan: Year 1 Progress

(SLC-050) Effectiveness of booster (third-dose) COVID-19 vaccination during pregnancy: a target trial emulation study using 4 European databases

(A-338) Evaluating the Diagnostic Accuracy of Adverse Events of Special Interest Following Janssen COVID-19 Vaccine (JCOVDEN) Using the VAC4EU Validation Pipeline

(A-341) Incidence of herpes zoster and vaccination rates in VA long-stay nursing home residents

(A-348) Incidence of human metapneumovirus among older adults in 10 high-income countries: a systematic literature review, meta-analysis, and modeling study

(A-333) Incidence Rates of Safety Events of Interest in a Post-Approval Study of Pfizer-BioNTech Original Monovalent COVID-19 Vaccine in the United States: Primary Series Analysis

(A-334) Incidence rates of safety outcomes in a post-approval study of the Pfizer-BioNTech monovalent COVID-19 vaccine in the United States, booster dose analysis

(A-335) Leveraging Real-World Data for Regulatory Commitment: Methodological Considerations in a Post-Approval Safety Study Evaluating the Risk of Atrial Fibrillation (AF) Following Respiratory Syncytial Virus (RSV) Vaccination

(A-354) Methods for Estimating Background Rates of Obstetric and Adverse Events of Special Interest During Pregnancy: A Multi-Site Analysis of Over 3 Million Annual Births

(A-332) Monitoring safety of Moderna COVID-19 vaccines in pregnancy: a multi-database study in Denmark, Norway, Spain and the United Kingdom. A regulator-mandated postauthorisation safety study in the VAC4EU network (EUPAS44450).

(A-344) Opportunities and Challenges of Using Brazilian Databases in Vaccine Pregnancy Registry Studies

(A-347) Patient and Epidemiological Factors Associated with Respiratory Syncytial Virus (RSV) Testing in Adults Hospitalized with RSV-Like Illness, 2023–2024 Respiratory Season

(A-355) Post-marketing safety surveillance for bivalent human papillomavirus vaccine in a regional healthcare database in China

(A-336) Regional differences in COVID-19 vaccine uptake and their determinants among Swedish older adults

(SLC-054) Risk factors for myocarditis/pericarditis following mRNA-1273 vaccination: interim analysis of a VAC4EU case-cohort study

(SLC-049) Risk of Atrial Fibrillation After Bivalent COVID-19 Vaccination During the 2022-2023 Season

(SLC-053) Risk of Venous Thrombosis With Thrombocytopenia Syndrome After Vaccination With AZD1222: A European VAC4EU Post-Authorisation Safety Study

(SLC-052) Safety Evaluation of Multiple Vaccination Regimens for the Elderly in Japan: The VENUS Study

(A-329) Safety Monitoring of Health Outcomes following Influenza Vaccination during the 2023–2024 Season among U.S. individuals aged 6 months through 64 years

(B-308) Safety Monitoring of Mpox Vaccines in Adults Aged 18–64 Years during the 2022 Mpox Outbreak in the U.S.

(A-331) Safety Monitoring of Multiple Health Outcomes following 2023–2024 COVID-19 Vaccination among Commercial Health Plan Enrollees Aged 6 Months–64 Years in the United States

(A-342) Safety of COVID-19 vaccination among patients with autoimmune diseases in Korea: a population-based self-controlled case series study

(A-356) Safety Profile of Vaxzevria® COVID-19 Vaccine in the COVID-19 Vaccines International Pregnancy Exposure Registry (C-VIPER)

(A-360) Social Disparities in HPV Vaccination Uptake Among Adolescent Girls in France (2007–2023)

(A-330) Type 1 Diabetes Mellitus in Individuals Receiving COVID-19 Messenger RNA Vaccination

(A-358) Using Tree-Based Scan Statistics to Monitor Routine Vaccines for Possible Associations with Guillain-Barré Syndrome in the Vaccine Safety Datalink

(A-359) Vaccine-related studies listed in the Heads of Medicines Agencies-European Medicines Agency (HMA-EMA) Catalogue of Real-World Data studies: What can we learn from study characteristics?

(A-361) Vaccinia vaccine effectiveness against mpox virus infections: a living literature review and evidence synthesis